Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“I think Aflac has put out a range of 170% to 230%.”
An analyst cites Aflac's disclosed ESR range as a benchmark for comparing Japan life insurers' new economic solvency ratio standards.
“And Japan Post Group, which is our alliance partner.”
Aflac's alliance partner Japan Post Group is performing well as a distribution channel for its Tsumitasu and cancer products in Japan.
“They include the final stage of the launch of Japan Post Insurance and Japan Post in April.”
Aflac completed the final rollout phase of its distribution alliance with Japan Post Insurance and Japan Post, contributing to strong Japan cancer insurance sales growth in the quarter.
“the partnership we launched that we had now flattish with SKYGEN they're doing a great job of the administrative services that they're providing for us behind the scenes. They are industry-leading third-party administrator out there, and we're pleased with what we've seen.”
SKYGEN is Aflac U.S.'s third-party administrator supporting the dental business, cited as a positive factor in the platform stabilization that helped dental sales recover in Q1.
“And Japan Post Insurance is not directly impacted by this recent news.”
Aflac clarifies that Japan Post Insurance, a separate entity within the Japan Post Group, is not affected by the data-misuse scandal at Japan Post Company.
“I believe that question is regarding the Japan Post companies inappropriate uses of non-publicized financial information.”
Japan Post Company, a key bank-channel distribution partner for Aflac's cancer insurance in Japan, is dealing with a data-misuse scandal that management says is having some impact on cancer insurance sales through that channel.
“Japan Post is taking a conservative approach to addressing this matter. The Japan Post Group is committed to selling your products and for our standard practice, Aflac Japan is in close communication with Japan Post Group at all levels of the organization. We'll continue to work closely with Japan Post Group in support of its sales of Aflac Cancer Insurance.”
Japan Post Group is a major distribution partner for Aflac Japan's cancer insurance; an unrelated data-sharing incident led Japan Post to take a conservative approach, but Aflac says the partnership and sales support continue without disclosed impact.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Tom Gallagher | Evercore ISI | 12 (25%) |
| Suneet Kamath | Jefferies | 10 (60%) |
| Jack Matten | BMO Capital Markets |
| John Barnidge | Piper Sandler | 9 (0%) |
| Wilma Burdis | Raymond James | 9 (0%) |
| Ryan Krueger | KBW | 8 (0%) |
| Joel Hurwitz | Dowling & Partners | 8 (38%) |
| Wes Carmichael | Wells Fargo | 8 (0%) |
| Jim Bhullar | JPMorgan | 8 (63%) |
| Alex Scott | Barclays | 7 (14%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wells Fargo | 3 | 13 (0%) |
| Evercore ISI | 1 | 12 (25%) |
| BMO Capital Markets | 2 | 12 (0%) |
| Jefferies | 1 | 10 (60%) |
| JPMorgan | 2 | 10 (50%) |
| Piper Sandler | 1 | 9 (0%) |
| Raymond James | 1 | 9 (0%) |
| KBW | 1 | 8 (0%) |
Aflac closed FY2025 with full-year adjusted EPS of $7.49 and a record $4.8 billion in capital returned to shareholders through buybacks and dividends. Japan sales grew 16% for the year with cancer products up 35.6%, and management raised 2026 Japan pretax margin guidance to 33-36%, above the prior Financial Analyst Briefing range of 30-33%. U.S. traditional individual sales were flat to negative despite group business growth, and Q4 adjusted EPS grew 0.6% ex-FX reflecting normalized margins after Q3's assumption unlock.
Demand | Product Launch | Margin | Capital Allocation | Competitive Dynamics | Regulation Policy | Macroeconomic | FX | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 7 | 6 | 5 | 3 | 5 | 3 | 4 | 1 |
| 2025Q1 | 7 | 4 | 2 | 5 | 3 | 3 | 5 | |
| 2025Q2 | 8 | 4 | 3 | 3 | 1 | 3 | 2 | |
| 2025Q3 | 7 | 5 | 4 | 3 | 3 | 1 | 1 | |
| 2025Q4 | 6 | 2 | 4 | 3 | 1 | 2 | 2 | |
| 2026Q1 | 1 | 2 | 4 | 3 | 3 | 2 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 7 | 7 | 8 | 7 | 6 | 1 |
| Product Launch | 6 | 4 | 4 | 5 | 2 | 2 |
| Margin | 5 | 2 | 3 | 4 | 4 | 4 |
| Capital Allocation | 3 | 5 | 3 | 3 | 3 | 3 |
| Competitive Dynamics | 5 | 3 | 1 | 3 | 1 | 3 |
| Regulation Policy | 3 | 3 | 3 | 2 | 2 | |
| Macroeconomic | 4 | 2 | 1 | 2 | 2 | |
| FX | 1 | 5 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
AFL Aflac | 6 | +25.0% | |
| GL Globe Life | 8 | +5.3% | |
| MET MetLife | 7 | +4.4% | |
| PRU Prudential Financial | 7 | +6.3% |